BiotechTube

BAF312 + Baseline disease modifying therapies (DMTs) + BNT162 + mRNA-1273

ApprovedCompleted
0 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Secondary Progressive Multiple Sclerosis

Conditions

Secondary Progressive Multiple Sclerosis

Trial Timeline

Apr 19, 2021 → Aug 15, 2022

NCT ID
NCT04792567

About BAF312 + Baseline disease modifying therapies (DMTs) + BNT162 + mRNA-1273

BAF312 + Baseline disease modifying therapies (DMTs) + BNT162 + mRNA-1273 is a approved stage product being developed by Novartis for Secondary Progressive Multiple Sclerosis. The current trial status is completed. This product is registered under clinical trial identifier NCT04792567. Target conditions include Secondary Progressive Multiple Sclerosis.

What happened to similar drugs?

5 of 20 similar drugs in Secondary Progressive Multiple Sclerosis were approved

Approved (5) Terminated (0) Active (15)
🔄KHK7580Kyowa KirinPhase 3
🔄KHK7580Kyowa KirinPhase 3
✅Cinacalcet HClKyowa KirinApproved
🔄KHK7580 + Cinacalcet HydrochlorideKyowa KirinPhase 3
🔄paricalcitol + maxacalcitol + paricalcitol placebo + maxacalcitol placeboAbbViePhase 3
✅Paricalcitol + CalcifediolAbbVieApproved
✅Paricalcitol + Darbepoetin alfaAbbVieApproved

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04792567ApprovedCompleted

Competing Products

20 competing products in Secondary Progressive Multiple Sclerosis

See all competitors
ProductCompanyStageHype Score
ASP7991 + Cinacalcet + PlaceboAstellas PharmaPhase 2
35
FycompaEisaiPre-clinical
26
FycompaEisaiPre-clinical
26
KHK7580 + KRN1493Kyowa KirinPhase 2/3
38
KHK7580Kyowa KirinPhase 1
29
KHK7580Kyowa KirinPhase 3
40
KHK7580Kyowa KirinPhase 3
40
Cinacalcet HClKyowa KirinApproved
43
KHK7580 + Cinacalcet HydrochlorideKyowa KirinPhase 3
40
Placebo + KHK7580 low dose + KHK7580 middle dose + KHK7580 high dose + KRN1493Kyowa KirinPhase 2
35
dirucotide + PlaceboEli LillyPhase 2/3
38
dirucotideEli LillyPhase 2/3
30
Paricalcitol + CalcitriolAbbViePre-clinical
18
paricalcitol + maxacalcitol + paricalcitol placebo + maxacalcitol placeboAbbViePhase 3
40
Paricalcitol + CalcifediolAbbVieApproved
43
Paricalcitol + Darbepoetin alfaAbbVieApproved
43
Birabresib Dose 20 mgMerckPhase 1
21
Remibrutinib (blinded) + Placebo + Remibrutinib (Open label)NovartisPhase 3
47
RanibizumabNovartisApproved
43
Ranibizumab 0.5mg + Ranibizumab 0.5 mg + Verteporfin PDTNovartisPhase 3
40